2 Information about cenobamate

Marketing authorisation indication

2.1 Cenobamate (Ontozry, Arvelle Therapeutics) is indicated for the 'adjunctive treatment of focal onset seizures with or without secondary generalisation in adults with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products'.

Dosage in the marketing authorisation

2.2 The dosage schedule for cenobamate is available in the summary of product characteristics.


2.3 Titration packs of 14 to 28 tablets are available in different doses ranging from 12.5 mg to 200 mg and costing between £85.54 to £165.62 per pack. Maintenance packs of 28 tablets are available in doses ranging from 50 mg to 200 mg costing £91 to £182 per pack. Estimated cost for the maintenance phase of treatment is £206 per person every 28 days (£7.37 per day).

  • National Institute for Health and Care Excellence (NICE)